Factors influencing the oxidation of the radioprotector WR-1065. 1988

H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
Department of Radiology, Case Western Reserve University, Cleveland, Ohio 44106.

N-(2-Mercaptoethyl)-1,3-diaminopropane (WR-1065) is the free thiol form of the radio- and chemoprotector S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). Interest currently exists in the clinical use of WR-2721 and WR-1065 as radio- and chemoprotectors of normal tissues. However, measurement of plasma levels of WR-1065 has proven difficult, due to rapid drug oxidation. Therefore, we studied factors influencing the oxidation of WR-1065, in Hepes-buffered saline as well as in tissue culture media containing 10% fetal bovine serum. The rate of oxygen consumption by WR-1065, as determined using the Clark oxygen electrode system, was faster in medium plus serum than in Hepes-buffered saline. That this effect is largely due to the presence of trace metal ions in tissue culture media and serum was indicated by the observation that addition of Cu2+ or Fe3+ to buffer stimulated oxygen consumption. Addition of KCN inhibited the reaction of WR-1065 with oxygen, and this effect was dependent on KCN concentration. That KCN blocked WR-1065 oxidation to the disulfide was verified using Ellman's reagent to quantitate the free thiol form. The rate of oxygen consumption was shown to be affected by temperature as well as concentration of WR-1065. Catalase reduced the rate of oxygen consumption of WR-1065, indicating that peroxide is formed in this system. Superoxide dismutase had a stimulatory effect. WR-1065 was found to stimulate the hexose monophosphate shunt in A549 cells. Since this stimulation was prevented by the presence of catalase, it appeared to be due to the response of the cells to peroxide, formed as a result of WR-1065 autooxidation.

UI MeSH Term Description Entries
D008624 Mercaptoethylamines Ethylamines, including CYSTEAMINE, that contain a sulfhydryl group in their structure.
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D011837 Radiation-Protective Agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. Radiation Protectant,Radiation Protective Agent,Radiation-Protective Agent,Radiation-Protective Drug,Radioprotective Agent,Radioprotective Agents,Radioprotective Drug,Agents, Radiation-Protective,Radiation Protectants,Radiation Protective Agents,Radiation-Protective Drugs,Radiation-Protective Effect,Radiation-Protective Effects,Radioprotective Drugs,Agent, Radiation Protective,Agent, Radiation-Protective,Agent, Radioprotective,Agents, Radiation Protective,Agents, Radioprotective,Drug, Radiation-Protective,Drug, Radioprotective,Drugs, Radiation-Protective,Drugs, Radioprotective,Effect, Radiation-Protective,Effects, Radiation-Protective,Protectant, Radiation,Protectants, Radiation,Protective Agent, Radiation,Protective Agents, Radiation,Radiation Protective Drug,Radiation Protective Drugs,Radiation Protective Effect,Radiation Protective Effects
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
March 1990, International journal of radiation biology,
H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
November 1992, Cell proliferation,
H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
June 1985, International journal of radiation oncology, biology, physics,
H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
September 1984, International journal of radiation oncology, biology, physics,
H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
September 1984, International journal of radiation oncology, biology, physics,
H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
June 2000, Radiation research,
H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
January 2002, Journal of AOAC International,
H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
June 2001, The Journal of pharmacology and experimental therapeutics,
H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
June 1994, Cancer letters,
H I Tahsildar, and J E Biaglow, and M M Kligerman, and M E Varnes
January 1990, Drug metabolism and disposition: the biological fate of chemicals,
Copied contents to your clipboard!